[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649812":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":37,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":26,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":26,"enrollmentInfo":49,"targetDuration":26,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":26,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":26},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group - Nicotinamide","EXPERIMENTAL","3000 mg nicotinamide administered the morning of surgery",[13],"Dietary Supplement: Nicotinamide (NAM)",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","PLACEBO_COMPARATOR","Placebo administered orally the morning of surgery",[19],"Dietary Supplement: Placebo control",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Nicotinamide (NAM)","A one time 3000 mg nicotinamide dose administered orally on the morning of cardiac surgery",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo control","A visually identically placebo",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Mark J. Robitaille, MD","CONTACT","(617) 667-3112","mrobitai@bidmc.harvard.edu",{"type":38,"investigatorFullName":39,"investigatorTitle":40,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Mark Robitaille","Principal Investigator","100649812","nad-supplementation-to-reduce-the-incidence-of-cardiac-surgery-associated-acute-kidney-injury-100649812",false,"NCT07739290","NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Undergoing coronary artery bypass graft (CABG) and\u002For valve surgery with cardiopulmonary bypass (CPB) at BIDMC. Includes combination surgeries that involve CABG and\u002For valve plus other procedures (e.g., Maze procedure, aortic aneurysm repair).\n3. AKI risk score ≥6 at the time of screening\n\nExclusion Criteria:\n\n1. History of AKI in the seven days prior to surgery, defined as any of the following:\n\n   * Increase in serum creatinine ≥0.3 mg\u002Fdl in 48h\n   * Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use most recent value in last 3 months)\n   * Urine output ≤0.5 ml\u002Fkg\u002Fh x 6 consecutive hours (only assessed in patients with hourly monitoring via Foley catheter)\n   * Receipt of renal replacement therapy (RRT) within 7d\n2. Advanced chronic kidney disease (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2 or end-stage kidney disease receiving RRT)\n3. Pregnant or breastfeeding\\*\n4. Positive COVID test in the last 10 days.\n5. Prisoner or institutionalized\n6. Existing or anticipated durable VAD\n\n8\\. Conflict with other studies\n\n9\\. Previous usage of nicotinamide supplements in the past 30 days","ALL","18 Years",{"count":50,"type":51},20,"ESTIMATED","INTERVENTIONAL",[54],"NA","The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.",[57],"Acute Kidney Injury",[59,60,61],"Acute kidney injury","nicotinamide adenine dinucleotide","cardiac surgery","NOT_YET_RECRUITING","2026-07-29",{"date":65,"type":66},"2026-07-31","ACTUAL",{"date":68,"type":51},"2026-09-01",{"date":70,"type":51},"2029-01-01",{"name":5,"class":6}]